Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Set Alert for Cardiovascular

First Phase III Success Opens Up Cardiovascular Pathway For Arrowhead

Arrowhead could have its first in-house RNA therapy on the market by 2025, with big plans to expand its reach in cardiometabolic disease, following a pivotal trial hit.

Companies Commercial

First Results Keep AstraZeneca’s Hopes High For Oral PCSK9 Inhibitor

AstraZeneca is looking to speed AZD0780 into Phase III development after it achieved a 78% total LDL cholesterol reduction in a Phase I study when used in combination with rosuvastatin. The firm needs to play catch up with its oral rivals.

Clinical Trials Companies

Cytokinetics’ Aficamten Data Could Be Best In Class, Cardiologists Say

The company released detailed data from the Phase III SEQUOIA-HCM trial testing the cardiac myosin inhibitor in patients with obstructive hypertrophic cardiomyopathy at Heart Failure 2024.

Cardiovascular Clinical Trials

Merck Investors Keeping A Close Watch On Winrevair Uptake

Some patients have already been prescribed the new drug for pulmonary arterial hypertension but Merck & Co. did not provide any sales or guidance. 

Sales & Earnings Launches

BMS Has A Strong Pipeline, But Access Challenges Remain

Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.

Business Strategies Clinical Trials

Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company

The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.

Sales & Earnings Commercial

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.

Research & Development Strategy

Olmesartan Unlikely To Eclipse Overall Benefit Of Alnylam's Zilebesiran

The lower benefit in the olmesartan arm of KARDIA-2 could draw scrutiny, but the company said it was expected and noted polypharmacy is common in hypertension.

Clinical Trials Cardiovascular

Semaglutide Might Treat Heart Failure Directly

Novo Nordisk’s product’s reputation as a wonder drug grows as new data suggest it might be disease-modifying in heart failure.

Clinical Trials Metabolic Disorders

Keeping Up The Pressure In Pulmonary Arterial Hypertension

Merck & Co leads a market expected to exceed $10bn by 2028, but others are aiming to muscle in.

Clinical Trials Commercial

With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy

The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.

Approvals Launches

Novo Pumps Up Heart Failure Prospects With Cardior Purchase

The Danish drugmaker is spending some of its semaglutide cash on a mid-stage RNA-based heart failure therapy developed by the German biotech.

M & A Cardiovascular
See All